Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival

Yang, Yi; Chen, Yi; Ye, Feng; Cao, Xiaojing; Xin, Yujing; Wang, Yanan; Lei, Yong; Li, Xiao; Feng, Dan; Zhou, Xiang; Fan, Qi-Wen

doi:10.1007/s00330-020-07460-x

Cited by 33 publications

(27 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The t-AUCs of the nomogram for predicting 3-, 4-, and 5-year RFS were 0.813, 0.781, and 0.723, respectively. 13 …”

Section: Discussionmentioning

confidence: 99%

“…The patients that developed early recurrence or died within 2 years after RFA were excluded, because this study mainly focused on late recurrence. 15 , 24 …”

Section: Methodsmentioning

confidence: 99%

“… 20 All the relevant parameters based on previous studies were tested before RFA. 12 , 24 , 25 The cut-off value of the parameters was set as the upper limit of the normal range at laboratory of NCC of China. Tumors at unfavorable locations were those located <0.5 cm from vital structures, such as major vessels (inferior vena cava, main hepatic artery, and the first and second branch of the portal vein), stomach, small bowel, colon, primary and secondary intrahepatic bile ducts, gallbladder, diaphragm, and pericardium.…”

Section: Methodsmentioning

confidence: 99%

“…Tumors at unfavorable locations were those located <0.5 cm from vital structures, such as major vessels (inferior vena cava, main hepatic artery, and the first and second branch of the portal vein), stomach, small bowel, colon, primary and secondary intrahepatic bile ducts, gallbladder, diaphragm, and pericardium. 24 …”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

Yang

Zhou

Zhang

et al. 2021

JHC

Self Cite

View full text Add to dashboard Cite

Objective This study was conducted to explore the application of age-male-ALBI-platelets (aMAP) score for predicting late recurrence of hepatocellular carcinoma (HCC) following radiofrequency ablation (RFA) and develop an aMAP score based-nomogram to predict prognosis in Chinese population. Materials and Methods HCC patients who developed late recurrence following RFA at National Cancer Center (NCC) of China, First Hospital of Shanxi Medical University and Beijing Hospital of Traditional Chinese Medicine from January 2011 to December 2016 were included as a training cohort, and patients who were treated at Affiliated Cancer Hospital of Zhengzhou University between January 2012 and December 2016 were included as an external validation cohort. The optimal cut-off value for aMAP score was determined using X-tile software to discriminate the performance of recurrence-free survival (RFS). Results A total of 339 eligible patients were included in this study. Patients were grouped into low-risk (aMAP score ≤64.2), medium-risk (64.3 ≤aMAP score ≤68.6) and high-risk (aMAP score ≥68.7) groups by X-tile plots. The prognostic factors that affected RFS were the number of lesions and aMAP score. A nomogram was constructed to predict the RFS with a C-index of 0.793 (95% CI: 0.744–0.842). The time-dependent receiver operating characteristic curves (t-AUCs) of the nomogram to predict 3, 4 and 5-year RFS were 0.808, 0.820 and 0.764, respectively. The model was then tested with data from an external validation cohort. The calibration curve confirmed the optimal agreement between the predicted and observed values. Conclusion The aMAP score provided a well-discriminated risk stratification and is an independent prognostic factor for the late recurrence of HCC following RFA. The aMAP score-based nomogram could help to strengthen prognosis-based decision making and formulate adjuvant therapeutic and preventive strategies.

show abstract

“…The t-AUCs of the nomogram for predicting 3-, 4-, and 5-year RFS were 0.813, 0.781, and 0.723, respectively. 13 …”

Section: Discussionmentioning

confidence: 99%

“…The patients that developed early recurrence or died within 2 years after RFA were excluded, because this study mainly focused on late recurrence. 15 , 24 …”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

Yang

Zhou

Zhang

et al. 2021

JHC

Self Cite

View full text Add to dashboard Cite

show abstract

“…With an annual incidence of 2.5 percent and a mortality rate of 2.75 percent, it is India's 14 th most common malignancy. 4 In preclinical studies, the oncogenic potential of human epidermal growth factor receptor 2 (HER2) has been identified, as well as in clinical environments Among the four members of the HER family of proteins, HER2 is a proto-oncogene with catalytic kinase activity and functions. 5,6 Reduced cell to cell adhesiveness helps cancer cells to break the histological structure of tumour tissue, allowing the tumour to dedifferentiate.…”

Section: Introductionmentioning

confidence: 99%

A histopathological evaluation of gall bladder cancer with special reference to HER2/neu and E-cadherin in Southern part of Assam

Choudhury

Deka

et al. 2021

Int J Res Med Sci

View full text Add to dashboard Cite

Background/Objective: Gall bladder carcinoma (GBC) is an aggressive malignancy with high mortality and aggressive course, with palliation as the only available option. The signs and symptoms of gall bladder arcinoma are not specific and often present late. Diagnosis is, therefore, often made at advanced stage with poorer outcomes. Identifying biomarkers and cancer specific cellular targets, that will pave the way for novel therapeutic approaches and early diagnosis for gall bladder carcinoma, is urgently needed. Proto-oncogenes (HER-2) and E-Cadherin are commonly deregulated in gallbladder cancer (GBC). This study evaluates the prognostic significance of HER-2 and E-Cadherin in GBC patients in Silchar Medical College.Our main objective was to evaluate frequency of HER-2/neu overexpression in GBC and to seek its correlation, if any with conventional clinicopathological parameters and survival.Methods: A total of 168 cases were received and evaluated for Gall Bladder cancer and control specimens were prospectively collected from 2018-2020. Immunohistochemical staining was done using monoclonal antibodies to semiquantitatively evaluate HER-2 and E-Cadherin protein expression. The criterion for HER-2 and E-Cadherin positivity was set at 10% and >5% tumor cells showing complete, membranous staining. Clinicopathological correlations were drawn with major clinical outcomes. Results: It was observed that out of 168 cases the male to female ratio is 1:5 with highest number of cases in the age group of 50-59 , i.e., 70 cases with 41.7%. The most common location in this study was fundus with 69% of cases (116 out 0f 168), most commonly presented as biliary colic with 56 number of cases. Grading was also done in 168 cases where most number of cases were moderately differentiated with 86 number of cases with a percentage of 51%. Expression of Her2Neu and E-Cadherin was evaluated where highest number of cases were seen with 1+ score in the IHC expressions of both the markers with 81 and 61 number of cases respectively. Conclusion: The increasing global incidence, late presentation leading to poor prognosis and lack of effective therapy make the management of gall bladderv carcinoma really challenging. Our study shows the abnormal expression of HER-2 and E-Cadherin expression in gall bladder carcinoma patients in Southern Assam and suggests that these two markers can be used for potential tool for early detection of gall bladder carcinoma and also can be used for targeted therapy in gall bladder carcinoma.

show abstract

Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy

She,

Shi,

Zhu

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer‐related death worldwide. Hepatectomy remains the first‐line treatment for patients with resectable HCC. However, the reported recurrence rate of HCC at 5 years after surgery is between 50% and 70%. Tumor‐related factors, including tumor size, number and differentiation, and underlying liver disease are well‐known risk factors for recurrence after treatment. In addition to tumor‐related factors, ever‐increasing amounts of studies are finding that the tumor microenvironment also plays an important role in the recurrence of HCC, including systemic inflammatory response and immune regulation. Based on this, some inflammatory and immune markers were used in predicting postoperative cancer recurrence. These include neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, cytotoxic T cells, and regulatory T cells, among others. In this review, we summarized the inflammatory and immune markers that affect recurrence after HCC resection in order to provide direction for adjuvant therapy after HCC resection and ultimately achieve the goal of reducing recurrence.

show abstract

Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival

Cited by 33 publications

References 42 publications

Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study

A histopathological evaluation of gall bladder cancer with special reference to HER2/neu and E-cadherin in Southern part of Assam

Impact of inflammation and the immune system on hepatocellular carcinoma recurrence after hepatectomy

Contact Info

Product

Resources

About